A novel monoclonal antibody targeting DCLK1 alternative splice variants-positive cells blocked RCC tumorigenesis in vivo and siRNA mediated knockdown of DCLK1 resulted in decreased expression of EMT and pluripotency factors in RCC15,.16 This evidence concerns the gene DCLK1 and renal cell carcinoma.